These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19519459)

  • 21. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A.
    Zhang Y; Schmidt RJ; Foxworthy P; Emkey R; Oler JK; Large TH; Wang H; Su EW; Mosior MK; Eacho PI; Cao G
    Biochem Biophys Res Commun; 2005 Aug; 334(2):729-32. PubMed ID: 16018973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niacin: its value in raising HDL cholesterol is being questioned.
    Heart Advis; 2011 Oct; 14(10):7. PubMed ID: 23019714
    [No Abstract]   [Full Text] [Related]  

  • 23. Nicotinic acid receptor subtypes and their ligands.
    Soudijn W; van Wijngaarden I; Ijzerman AP
    Med Res Rev; 2007 May; 27(3):417-33. PubMed ID: 17238156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and characterization of GSK256073, a non-flushing hydroxy-carboxylic acid receptor 2 (HCA2) agonist.
    Sprecher D; Maxwell M; Goodman J; White B; Tang CM; Boullay V; de Gouville AC
    Eur J Pharmacol; 2015 Jun; 756():1-7. PubMed ID: 25773497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avoid no-flush niacin in favor of the prescription version. Follow certain steps to reduce the flushing effects of prescription niacin.
    Heart Advis; 2010 Nov; 13(11):5. PubMed ID: 22834056
    [No Abstract]   [Full Text] [Related]  

  • 26. New evidence for nicotinic acid treatment to reduce atherosclerosis.
    Montecucco F; Quercioli A; Dallegri F; Viviani GL; Mach F
    Expert Rev Cardiovasc Ther; 2010 Oct; 8(10):1457-67. PubMed ID: 20936932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a novel niacin-lipoic acid dimer N2L attenuating atherosclerosis and dyslipidemia with non-flushing effects.
    Jiang Y; Jin M; Chen J; Yan J; Liu P; Yao M; Cai W; Pi R
    Eur J Pharmacol; 2020 Feb; 868():172871. PubMed ID: 31846627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Niacin for dyslipidemia: considerations in product selection.
    McKenney J
    Am J Health Syst Pharm; 2003 May; 60(10):995-1005. PubMed ID: 12789870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Randomized, Placebo-Controlled Trial to Assess the Effects of 8 Weeks of Administration of GSK256073, a Selective GPR109A Agonist, on High-Density Lipoprotein Cholesterol in Subjects With Dyslipidemia.
    Olson EJ; Mahar KM; Haws TF; Fossler MJ; Gao F; de Gouville AC; Sprecher DL; Lepore JJ
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):871-883. PubMed ID: 31268250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Niacin into the void. Failure of HDL cholesterol drug may B this vitamin's big chance.
    Harv Health Lett; 2007 Apr; 32(6):6. PubMed ID: 17390509
    [No Abstract]   [Full Text] [Related]  

  • 31. Correction of low HDL cholesterol to reduce cardiovascular risk: practical considerations relating to the therapeutic use of prolonged-release nicotinic acid (Niaspan).
    Vogt A; Kassner U; Hostalek U; Steinhagen-Thiessen E
    Int J Clin Pract; 2007 Nov; 61(11):1914-21. PubMed ID: 17935550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pyrazole partial agonists on HCA(2) -mediated flushing and VLDL-triglyceride levels in mice.
    Li Z; Blad CC; van der Sluis RJ; de Vries H; Van Berkel TJ; Ijzerman AP; Hoekstra M
    Br J Pharmacol; 2012 Oct; 167(4):818-25. PubMed ID: 22616721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel patent publications on high-affinity nicotinic acid receptor agonists.
    Shen HC; Colletti SL
    Expert Opin Ther Pat; 2009 Jul; 19(7):957-67. PubMed ID: 19552512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G).
    Tunaru S; Lättig J; Kero J; Krause G; Offermanns S
    Mol Pharmacol; 2005 Nov; 68(5):1271-80. PubMed ID: 16099840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyrido pyrimidinones as selective agonists of the high affinity niacin receptor GPR109A: optimization of in vitro activity.
    Peters JU; Kühne H; Dehmlow H; Grether U; Conte A; Hainzl D; Hertel C; Kratochwil NA; Otteneder M; Narquizian R; Panousis CG; Ricklin F; Röver S
    Bioorg Med Chem Lett; 2010 Sep; 20(18):5426-30. PubMed ID: 20724150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nicotinic acid in lipid metabolism disorders].
    Ahmed K; Offermanns S
    Pharm Unserer Zeit; 2007; 36(2):120-5. PubMed ID: 17424997
    [No Abstract]   [Full Text] [Related]  

  • 37. Mechanism of action of niacin.
    Kamanna VS; Kashyap ML
    Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pleiotropic effects of niacin: Current possibilities for its clinical use.
    Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
    Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors.
    Zellner C; Pullinger CR; Aouizerat BE; Frost PH; Kwok PY; Malloy MJ; Kane JP
    Hum Mutat; 2005 Jan; 25(1):18-21. PubMed ID: 15580557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More on niacin: no flush, no good.
    Harv Health Lett; 2007 Jul; 32(9):7. PubMed ID: 17663076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.